Loading clinical trials...
Loading clinical trials...
A Phase II Clinical Study of Oral Suberoylanilide Hydroxamic Acid in Patients With Relapsed or Refractory Breast, Colorectal, and Non-small Cell Lung Cancer.
Conditions
Interventions
MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA)
Duration of Treatment - During each treatment cycle, treatment is administered twice daily for 14 days, followed by 7 days of rest for a total of 10 cycles
Start Date
December 1, 2004
Primary Completion Date
October 11, 2005
Completion Date
October 11, 2005
Last Updated
April 10, 2017
NCT04550494
NCT04704661
NCT05245812
NCT06696768
NCT05673200
NCT05372640
Lead Sponsor
Merck Sharp & Dohme LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions